Novo Nordisk’s Pill Win Offers a Short?Term Lift, but the 2027 Price?Cut Storm Is Already on the Horizon
Published on 07/18/2026 at 04:11 | Redaktion boerse-global.de
Novo Nordisk’s shares have climbed more than 15% over the past 30 days, yet the stock still trades nearly 28% below its 52?week high — a rally that arrived on the back of two potent catalysts. First, the European Medicines Agency’s human medicines committee gave a green light for the oral Wegovy tablet, a once?daily 25?milligram semaglutide dose that makes Novo the first company to bring an oral GLP?1 weight?loss drug to the European market. Second, the Danish drugmaker is ploughing ahead with a share buyback programme worth up to 15 billion Danish kroner, set to run for twelve months from February 2026.
The euphoria, however, masks a structural challenge that has yet to hit the income statement. Novo Nordisk plans to cut the list prices for Wegovy and Ozempic in the United States from January 2027, partly as a result of the “Most Favored Nation” pricing framework. The company’s own 2026 guidance already anticipates a 4% to 12% decline in constant?currency revenue growth, and the deeper price concessions are still a year away. The critical question is whether Novo can ramp up US prescription volumes and international market share fast enough to absorb the margin squeeze that 2027 will bring.
The Pill Advantage and the Volume Gambit
The European approval for oral Wegovy is based on the OASIS?4 study, where patients with good compliance shed an average of 16.6% of their body weight, and one?third lost at least 20%. Eli Lilly has yet to secure a similar European filing for its own oral obesity therapy, handing Novo a meaningful head start in the race for the continent’s pill?based weight?loss market. Meanwhile, the company’s dual GLP?1/amylin agonist Amycretin showed in a Type 2 diabetes trial a reduction in HbA1c of up to 1.71 percentage points and weight loss of as much as 14.6% at the 40?mg dose, with no plateau evident — a signal that further efficacy gains may be achievable.
Management is leaning heavily on volume growth to offset the coming price pressure. Wegovy, Wegovy HD and the new oral pill are being pushed through the self?pay channel via NovoCare Pharmacy and telehealth partnerships, while the international rollout of the Wegovy portfolio will accelerate through 2026. The buyback programme, which has already retired nearly 44% of its annual target, provides a floor under the stock in the near term.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Bear Case: Price Erosion and a Pipeline Risk
The more cautious view holds that the pricing headwinds are only beginning. The MFN agreement and the loss of semaglutide exclusivity in some international markets are already embedded in a guidance that projects a full?year revenue decline. Competition is intensifying: Eli Lilly’s Zepbound outperformed Novo’s successor candidate CagriSema in a head?to?head Phase 3 weight?loss study, leaving the commercial future of CagriSema entirely dependent on an FDA decision expected by the end of 2026. Any launch would not occur before late 2026 or early 2027, leaving a long window of uncertainty.
If US volume growth disappoints while the 2027 price cuts take effect as planned, the margin compression could overwhelm the technical support provided by the buyback. The stock’s 52?week low of €30.25 — from which the current rally has rebounded — remains a plausible destination should the volume story falter.
Analysts Remain Split
HSBC recently lifted its price target to 300 Danish kroner from 280, while the broader analyst consensus shows seven buy ratings against two sell recommendations — a neutral tilt that reflects the competing forces at work. On the trading desk, the stock’s immediate reaction to the EU news was a minor 2.2% slip to €44.02, a sign that the market is already pricing in the longer?term risk.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The Next Catalyst
All eyes are now on Novo Nordisk’s upcoming quarterly earnings, which will offer a real?time reading of US pricing trends and the trajectory of prescription volumes. The data from that report will determine whether the bull case — built on oral Wegovy’s launch, a growing patient base and a multi?billion?dollar buyback — can sustain the rally, or whether the bear case, centred on 2027’s price cuts and an uncertain pipeline, will drag the shares back toward their lows.
Ad
Novo Nordisk Stock: New Analysis - 18 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
